Abstract
The fungal metabolite fumagillin suppresses the formation of new blood vessels, and a fumagillin analog is currently in clinical trials as an anticancer agent. The molecular target of fumagillin is methionine aminopeptidase-2 (MetAP-2). A 1.8 Å resolution crystal structure of free and inhibited human MetAP-2 shows a covalent bond formed between a reactive epoxide of fumagillin and histidine-231 in the active site of MetAP-2. Extensive hydrophobic and water-mediated polar interactions with other parts of fumagillin provide additional affinity. Fumagillin-based drugs inhibit MetAP-2 but not MetAP-1, and the three-dimensional structure also indicates the likely determinants of this specificity. The structural basis for fumagillin's potency and specificity forms the starting point for structure- based drug design.
Cite
CITATION STYLE
Liu, S., Widom, J., Kemp, C. W., Crews, C. M., & Clardy, J. (1998). Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science, 282(5392), 1324–1327. https://doi.org/10.1126/science.282.5392.1324
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.